The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2008: Volume 13/ Issue 3 Article 2
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 13, Issue 3, 17 January 2008
Rapid communications
Autochthonous chikungunya virus transmission may have occurred in Bologna, Italy, during the summer 2007 outbreak
  1. Communicable Disease Epidemiology Unit, National Centre of Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità (National Public Health Institute, ISS), Rome, Italy
  2. European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
  3. Public Health Service, Emilia-Romagna Region, Bologna, Italy
  4. Azienda Unità Sanitaria Locale (Local Health Unit, AUSL) of Bologna, Department of Public Health, Bologna, Italy
  5. University of Bologna, Azienda Ospedaliera Universitaria di Bologna, Microbiologia, Bologna, Italy
  6. National Centre of Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità (National Public Health Institute, ISS), Rome, Italy

Citation style for this article: Seyler T, Rizzo C, Finarelli AC, Po C, Alessio P, Sambri V, Ciofi Degli Atti ML, Salmaso S. Autochthonous chikungunya virus transmission may have occurred in Bologna, Italy, during the summer 2007 outbreak. Euro Surveill. 2008;13(3):pii=8015. Available online:


In Italy, a national surveillance system for chikungunya fever coordinated by the National Public Health Institute has been in place since August 2006. In summer 2007, an outbreak of chikungunya fever affected the Italian provinces of Ravenna, Cesena-Forli and Rimini [1-3]. As of 16 December 2007, health authorities identified 214 laboratory-confirmed cases with date of onset from 15 July to 28 September 2007. Most cases (161) occurred in the two neighbouring villages of Castiglione di Cervia and Castiglione di Ravenna, but limited local transmission also took place in the cities of Ravenna, Cesena, Cervia, and Rimini. In September 2007, two confirmed cases (two women aged 68 and 70) were reported among residents of the city of Bologna (373,026 inhabitants). Both had a history of travel in the affected areas (municipality of Cervia). No unusual increase in the density of Aedes albopictus mosquitoes in the Bologna area was noted at that time (September).

On 17 December 2007, the Regional Health Authority of Emilia-Romagna reported that three further residents of Bologna had tested positive for IgG and IgM antibodies against chikungunya virus by using a commercially available immunofluorescence test performed in Bologna on 14 December on blood samples taken on 5 December. Confirmation from the national laboratory at the National Public Health Institute is pending. The three patients (two women aged 78 and 79, and a boy aged 14) had developed fever, arthralgia and rash on 7, 18 and 23 September respectively, but had not been identified as suspected cases of chikungunya fever at that time. Blood samples were taken as one patient complained of persisting joint pain and the other two had had similar symptoms.

All three patients lived on the first floor of the same building, with a garden. The building is 2.5 km from the closest previously identified cases with a travel history to Cervia, reported in September. According to direct interviews, these three patients did not visit or stay in the area of the two imported cases, and vice versa. In addition, none of these last three cases reported having been abroad or having visited the affected areas at the time of the outbreak.

As these cases remained undetected at an early stage, no specific vector control measures were implemented in their premises. However, monthly routine preventive measures in Bologna from April to October included the use of larvicide in public areas. The apartment block was was not considered a “public area” for larvicide treatment.

This finding suggests that transmission may have occurred 75 km away from the initial cluster. This could be explained by the importation of the virus in the area where the three cases live through an undetected (asymptomatic) viraemic patient. Another possible explanation is passive vector mobility (e.g. infected mosquitoes transported by car from the initial cluster), since the flight range (active mobility) is usually considered to be less than 1 km, The sensitivity of the surveillance system relies on the continued dissemination of information to physicians regarding the clinical symptoms (i.e. fever and severe arthralgia) that should prompt laboratory investigation for chikungunya virus infection. The present report highlights the need for reinforcing information and surveillance.



  1. Angelini R, Finarelli A, Angelini P, Po C, Petropulacos K, Macini P, et al. An outbreak of chikungunya fever in the province of Ravenna, Italy. Euro Surveill. 2007;12(9):E070906.1. Available from:
  2. Angelini R, Finarelli AC, Angelini P, Po C, Petropulacos K, Silvi G, et al. Chikungunya in north-eastern Italy: a summing up of the outbreak. Euro Surveill. 2007;12:E071122.2. Available from:
  3. Rezza G, Nicoletti L,Angelini R, Romi R. Finarelli AC, Panning M, et al. Infection with Chikungunya virus in Italy: an outbreak in a temperate region. Lancet. 2007;370(9602):1840-6.


Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.